提吉特
免疫组织化学
腺癌
医学
癌症研究
内科学
肿瘤科
癌症
免疫疗法
作者
Yu Sun,Jiping Luo,Yangshan Chen,Ji Cui,Yiyan Lei,Yongmei Cui,Neng Jiang,Wenting Jiang,Lili Chen,Yanyang Chen,Yukun Kuang,Kejing Tang,Zunfu Ke
标识
DOI:10.1016/j.intimp.2020.106198
摘要
The interaction between CD155 and its high-affinity ligand TIGIT is being increasingly investigated in various solid tumors. However, the prognostic significance of CD155 and TIGIT in lung adenocarcinoma (LUAD) remains unclear. In this study, immunohistochemistry was applied in 334 LUAD cases to evaluate the expression of CD155 and TIGIT. Western blotting was conducted in 5 paired primary LUAD and adjacent normal lung tissues. Our results reveal that CD155 and TIGIT are overexpressed in LUAD tissues and that aberrant overexpression is closely correlated with poor clinical outcomes (P < 0.01). The multivariate model also shows that CD155 expression is an independent risk factor for LUAD (RR, 1.34; P = 0.036). Moreover, patients expressing high CD155 and TIGIT simultaneously presented shorter overall survival (OS) (P < 0.01) and progression-free survival (PFS) (P < 0.01). These findings suggest that CD155 and TIGIT can make up a prognosticating tool to predict clinical outcomes, thereby contributing to personalized medical care in LUAD.
科研通智能强力驱动
Strongly Powered by AbleSci AI